Neurotrophins, including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and neurotrophin-3 (NT-3), have repeatedly been shown to be involved in the pathophysiology of Alzheimer's disease (AD). Recent studies have claimed that these neurotrophic factors are important tools for therapeutic intervention in neurodegenerative diseases. So far, little is known about the age- and disease-modulated time course of cerebral neurotrophins. Therefore, we have studied protein concentrations of BDNF, NGF, and NT-3 in different brain areas and sciatic nerve, a neurotrophin-transporting peripheral nerve, in a well-characterized AD model of amyloid precursor protein-overexpressing rodents (APP23 mice) at the ages of 5.0, 10.5, and 20.0 months. In APP23 mice, there was a significant increase of BDNF and NGF in the frontal and occipital cortices (for BDNF also in the striatum) of old 20.0-month-old mice (with respect to median values up to 8.2-fold), which was highly correlated with amyloid concentrations of these brain areas. Median values of NGF and NT-3 showed up to a 6.0-fold age-dependent increase in the septum that was not detectable in APP23 mice. Hippocampus, olfactory bulb, and cerebellum (except NT-3) did not show substantial age- or genotype-related regulation of neurotrophins. In the sciatic nerve, BDNF and NGF levels are increased in5-month-old APP23 mice and decrease with age to control levels. In conclusion, APP23 mice show a genotype-dependent increase of cortical BDNF and NGF that is highly correlated with amyloid concentrations and may reflect an amyloid-related glia-derived neurotrophin secretion or an altered axonal transport of these neurotrophic factors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jnr.21704 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
KIF9 Ameliorates Neuropathology and Cognitive Dysfunction by Promoting Macroautophagy in a Mouse Model of Alzheimer's Disease.
Aging Cell
January 2025
Growth, Development, and Mental Health of Children and Adolescence Center, Pediatric Research Institute, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China.
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder affecting the elderly. The imbalance of protein production and degradation processes leads to the accumulation of misfolded and abnormally aggregated amyloid-beta (Aβ) in the extracellular space and forms senile plaques, which constitute one of the most critical pathological hallmarks of AD. KIF9, a member of the kinesin protein superfamily, mediates the anterograde transport of intracellular cargo along microtubules.
View Article and Find Full Text PDFAPP lysine 612 lactylation ameliorates amyloid pathology and memory decline in Alzheimer's disease.
J Clin Invest
January 2025
Growth, Development, and Mental Health of Children and Adolescence Center, Pediatric Research Institute, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China.
Article Synopsis
- Posttranslational modification (PTM) of the amyloid precursor protein (APP), particularly lactylation, is linked to the development of Alzheimer's disease (AD), but its specific role is still unclear.
- Research showed reduced APP lactylation in AD patients and models, identifying lysine 612 as a key lactylation site, which affects APP processing and Aβ generation.
- A lactyl-mimicking mutant enhanced APP trafficking and reduced cognitive decline by modifying APP interactions, suggesting that targeting APP lactylation may offer new therapeutic avenues for Alzheimer's disease.
Efficient Seeding of Cerebral Vascular Aβ-Amyloidosis by Recombinant AβM1-42 Amyloid Fibrils.
J Mol Biol
February 2025
Department of Physics, Chemistry and Biology (IFM), Linköping University, 581 83 Linköping, Sweden. Electronic address:
Aβ-amyloid plaques and cerebral amyloid angiopathy (CAA) in the brain are pathological hallmarks of Alzheimer's disease (AD) and vascular dementia. The spreading of Aβ amyloidosis in the brain appears to be mediated by a seeding mechanism, where preformed fibrils (called seeds) accelerate Aβ fibril formation by bypassing the rate-determining nucleation step. Several studies have demonstrated that Aβ amyloidosis can be induced in transgenic mice, producing human Aβ, by injecting Aβ-rich brain extracts (seeds) derived from transgenic mice and human AD brains.
View Article and Find Full Text PDFDevelopment of a novel radioiodinated compound for amyloid and tau deposition imaging in Alzheimer's disease and tauopathy mouse models.
Neuroimage
December 2024
Department of Radiopharmacy and Molecular Imaging, Minhang Hospital & School of Pharmacy, Fudan University, Shanghai, China; Department of Functional Brain Imaging Research, China; Department of Clinical and Experimental Neuroimaging, Centre for Development of Advanced Medicine for Dementia, National Centre for Geriatrics and Gerontology, Obu, Japan; Key Laboratory of Smart Drug Delivery, Fudan University, Ministry of Education, Shanghai, China; Institute for Small-Molecule Drug Discovery & Development, Quzhou Fudan Institute, Quzhou, China. Electronic address:
Article Synopsis
- - The study focused on a new compound called AD-DRK (I-AD-DRK) that can non-invasively identify amyloid-β and tau deposits in the brain, which are critical for diagnosing Alzheimer's disease and related disorders.
- - Researchers conducted tests using this compound in both postmortem human brains and mouse models with amyloid and tau accumulation, demonstrating its effective binding and visualization capabilities in the brain regions associated with these proteins.
- - The results showed that I-AD-DRK has strong potential as a SPECT imaging agent, offering high-contrast imaging of amyloid and tau, which could significantly help in early diagnosis and treatment of Alzheimer's disease and other tauopathies.
The presence of circulating human apolipoprotein J reduces the occurrence of cerebral microbleeds in a transgenic mouse model with cerebral amyloid angiopathy.
Alzheimers Res Ther
July 2024
Neurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron, 119-129, Mediterranean Building, 1st floor, lab 106, Barcelona, 08035, Spain.
Background: Cerebral amyloid angiopathy (CAA) is characterized by amyloid-β (Aβ) deposition in cerebral vessels, leading to lobar cerebral microbleeds (CMB) and intracerebral hemorrhages (ICH). Apolipoprotein J (ApoJ) is a multifunctional chaperone related to Aβ aggregation and clearance. Our study investigated the vascular impact of chronic recombinant human Apolipoprotein J (rhApoJ) treatment in a transgenic mouse model of β-amyloidosis with prominent CAA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!